<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Ovulation induction with clomiphene citrate</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Ovulation induction with clomiphene citrate</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Ovulation induction with clomiphene citrate</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Emre Seli, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Aydin Arici, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert L Barbieri, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kathryn A Martin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 20, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">Clomiphene</a> citrate has been the most widely used treatment for fertility enhancement for the past 40 years. Clomiphene was a revolutionary advance in reproductive medicine and quickly became popular for induction of ovulation because of its ease of administration and minimal side effects. However, <a class="drug drug_general" data-topicid="10064" href="/d/drug information/10064.html" rel="external">letrozole</a>, an aromatase inhibitor, is also effective for ovulation induction in women with polycystic ovary syndrome (PCOS). Available data suggest that live birth rates are higher with letrozole than clomiphene, and many experts now suggest letrozole as first-line therapy for anovulatory women with PCOS.</p><p>The pharmacology, indications, and administration of <a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">clomiphene</a> citrate will be reviewed here. Other drugs for induction of ovulation, including <a class="drug drug_general" data-topicid="10064" href="/d/drug information/10064.html" rel="external">letrozole</a>, are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/7407.html" rel="external">"Overview of ovulation induction"</a> and  <a class="medical medical_review" href="/d/html/7425.html" rel="external">"Ovulation induction with letrozole"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">PHARMACOLOGY/MECHANISMS OF ACTION</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">Clomiphene</a> is a nonsteroidal triphenylethylene derivative distantly related to diethylstilbestrol. It acts as a selective estrogen receptor modulator (SERM), similar to <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a> and <a class="drug drug_general" data-topicid="9593" href="/d/drug information/9593.html" rel="external">raloxifene</a>. All three drugs are competitive inhibitors of estrogen binding to estrogen receptors (ERs) and have mixed agonist and antagonist activity, depending upon the target tissue. (See  <a class="medical medical_review" href="/d/html/762.html" rel="external">"Mechanisms of action of selective estrogen receptor modulators and down-regulators"</a>.)</p><p>The commercially available form of <a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">clomiphene</a> is the dihydrogen citrate salt (clomiphene citrate). It contains two stereoisomers: zu-clomiphene (38 percent) and en-clomiphene (62 percent), which were originally called the cis-isomer and trans-isomer, respectively. En-clomiphene is cleared rapidly, while zu-clomiphene has a long half-life [<a href="#rid1">1</a>]. The two clomiphene isomers have mixed estrogenic and antiestrogenic effects that vary among species. En-clomiphene is the more potent isomer with greater antiestrogenic activity and the one primarily responsible for inducing follicular development [<a href="#rid2">2</a>].</p><p><a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">Clomiphene</a> is cleared through the liver and excreted in feces. Over 50 percent of an oral dose of 14C-labeled clomiphene citrate is excreted after five days, but traces of radioactivity from the labeled clomiphene appear in the feces up to six weeks after administration. Although this observation raises concerns about fetal exposure to clomiphene, most studies suggest that the frequency of congenital malformations is not increased [<a href="#rid3">3</a>]. (See <a class="local">'Perinatal outcome'</a> below.)</p><p><a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">Clomiphene</a> citrate binds to ERs and exerts its major effects on the hypothalamus, pituitary, ovary, and uterus. Unlike estrogen, clomiphene citrate binds nuclear ERs for a prolonged period and depletes them [<a href="#rid1">1</a>].</p><p>Most evidence suggests that the primary site of <a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">clomiphene</a> action is the hypothalamus, where it appears to bind to and deplete hypothalamic ERs, thereby blocking the negative feedback effect of circulating endogenous estradiol [<a href="#rid4">4,5</a>]. This results in an increase in hypothalamic gonadotropin-releasing hormone (GnRH) pulse frequency [<a href="#rid6">6</a>] and increased serum concentrations of follicle-stimulating hormone (FSH) and luteinizing hormone (LH). In vitro data suggest that clomiphene citrate also has a pituitary site of action where it causes an increase in the gonadotropin response to GnRH [<a href="#rid7">7</a>]. (See  <a class="medical medical_review" href="/d/html/7438.html" rel="external">"Physiology of gonadotropin-releasing hormone"</a>.)</p><p>The ovarian actions of <a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">clomiphene</a> are for the most part secondary to the effects of elevated FSH and LH on ovarian follicular development (see  <a class="medical medical_review" href="/d/html/7418.html" rel="external">"Normal menstrual cycle"</a>). Clomiphene is an estrogen agonist in the absence of estrogen, thereby enhancing FSH stimulation of LH receptors in granulosa cells [<a href="#rid8">8</a>].</p><p><a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">Clomiphene</a> acts primarily as an antiestrogen in the uterus, cervix, and vagina. The following findings may explain why pregnancy rates are relatively low when ovulatory rates are so high in women administered clomiphene cycles:</p><p class="bulletIndent1"><span class="glyph">●</span>The normal increase in uterine volume and endometrial thickening that occurs during spontaneous menstrual cycles is largely absent during clomiphene-induced cycles, despite higher estradiol levels [<a href="#rid9">9,10</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Abnormal luteal phase endometrial morphology has been found in some [<a href="#rid11">11,12</a>], but not all [<a href="#rid13">13</a>], studies.</p><p></p><p>Data on the effect of <a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">clomiphene</a> on cervical mucus are conflicting. While one study found no detrimental effect [<a href="#rid14">14</a>], another noted a decrease in the quality and quantity of cervical mucus at all clomiphene doses [<a href="#rid15">15</a>]. In a meta-analysis, a detrimental effect was seen only with doses ≥100 mg/day [<a href="#rid16">16</a>].</p><p><a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">Clomiphene</a> citrate has no apparent progestational, corticotropic, androgenic, or antiandrogenic effects, nor does it interfere with adrenal or thyroid function.</p><p class="headingAnchor" id="H8"><span class="h1">PATIENT SELECTION</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">Clomiphene</a> citrate is used to induce ovulation in selected populations of anovulatory women and is used in women with ovulatory infertility to increase follicular number and fertility [<a href="#rid1">1</a>]. As noted, clomiphene citrate is now considered to be a second-line agent for women with polycystic ovary syndrome (PCOS) as <a class="drug drug_general" data-topicid="10064" href="/d/drug information/10064.html" rel="external">letrozole</a> therapy results in higher birth rates. (See  <a class="medical medical_review" href="/d/html/7425.html" rel="external">"Ovulation induction with letrozole"</a>.)</p><p>Its use in ovulatory infertility and for men with hypogonadism is reviewed separately. (See  <a class="medical medical_review" href="/d/html/7410.html" rel="external">"Unexplained infertility", section on 'Clomiphene citrate'</a> and  <a class="medical medical_review" href="/d/html/7452.html" rel="external">"Treatments for male infertility"</a>.)</p><p>The primary indication for the antiestrogen <a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">clomiphene</a> citrate is infertility secondary to oligoovulation or anovulation in women with PCOS [<a href="#rid1">1</a>]. Some amount of endogenous estrogen is necessary for a response to clomiphene; women with PCOS do produce estrogen (as evidenced by spontaneous menses or withdrawal bleeding in response to a <a class="drug drug_general" data-topicid="9817" href="/d/drug information/9817.html" rel="external">progesterone</a> challenge). Women who are hypoestrogenemic are unlikely to respond (eg, those with hypogonadotropic amenorrhea or primary ovarian insufficiency)  (<a class="graphic graphic_table graphicRef56718" href="/d/graphic/56718.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H9"><span class="h2">Polycystic ovary syndrome</span><span class="headingEndMark"> — </span>The approach to ovulation induction in women with PCOS is reviewed separately and summarized here briefly  (<a class="graphic graphic_table graphicRef56718" href="/d/graphic/56718.html" rel="external">table 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Weight loss</strong> – Weight loss should always be attempted before initiating ovulation induction in women with PCOS and obesity because ovulation can be restored with a modest amount of weight loss. If unsuccessful, a multistep approach to ovulation induction is then undertaken  (<a class="graphic graphic_table graphicRef56718" href="/d/graphic/56718.html" rel="external">table 1</a>). For infertile women with obesity who are &gt;40 years of age, clinicians need to balance the health benefits of weight loss against the loss of fertility potential that might occur due to a delay in initiation of ovulation induction. Fertility potential declines rapidly after 40 years of age.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Choice of </strong><a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">clomiphene</a><strong> versus </strong><a class="drug drug_general" data-topicid="10064" href="/d/drug information/10064.html" rel="external">letrozole</a> – Most, but not all, women with PCOS ovulate in response to clomiphene citrate. However, higher live birth rates have been observed with the aromatase inhibitor letrozole, particularly in patients with PCOS and obesity [<a href="#rid17">17</a>]. (See  <a class="medical medical_review" href="/d/html/7425.html" rel="external">"Ovulation induction with letrozole", section on 'Outcomes'</a>.)</p><p></p><p class="bulletIndent1">Many experts now suggest <a class="drug drug_general" data-topicid="10064" href="/d/drug information/10064.html" rel="external">letrozole</a> rather than <a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">clomiphene</a> citrate for all women with PCOS. Ovulation induction is an off-label use of letrozole. Efficacy and safety are reviewed in detail separately. (See  <a class="medical medical_review" href="/d/html/7425.html" rel="external">"Ovulation induction with letrozole"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">Metformin</a> – Metformin, a drug whose major effect is to reduce hepatic glucose output and lower serum insulin concentrations, has been used to promote ovulation, but its role is now limited as it appears to be less effective for pregnancy rates than <a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">clomiphene</a>. Clinical trial data supporting this are reviewed elsewhere. A consensus group has recommended against the routine use of metformin (including ovulation induction), except in women with glucose intolerance. (See  <a class="medical medical_review" href="/d/html/7411.html" rel="external">"Metformin for treatment of the polycystic ovary syndrome", section on 'Anovulatory infertility'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gonadotropins</strong> – Gonadotropin therapy is only considered for anovulatory women who have either not ovulated or not conceived after treatment with initial therapies (weight loss, <a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">clomiphene</a>, <a class="drug drug_general" data-topicid="10064" href="/d/drug information/10064.html" rel="external">letrozole</a>). Gonadotropin therapy is associated with a higher risk of multiple gestation and ovarian hyperstimulation syndrome than oral ovulation induction agents. (See  <a class="medical medical_review" href="/d/html/7407.html" rel="external">"Overview of ovulation induction", section on 'Gonadotropin therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laparoscopic ovarian drilling</strong> – Laparoscopic ovarian drilling may be considered in women with PCOS who fail to ovulate despite an adequate trial of <a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">clomiphene</a> citrate. (See  <a class="medical medical_review" href="/d/html/7421.html" rel="external">"Treatment of polycystic ovary syndrome in adults", section on 'Laparoscopic surgery'</a>.)</p><p></p><p class="headingAnchor" id="H11"><span class="h2">Other ovulatory disorders</span><span class="headingEndMark"> — </span>Women with hypogonadotropic hypogonadism (hypothalamic amenorrhea) are hypoestrogenemic and are therefore unlikely to respond to <a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">clomiphene</a> citrate, an antiestrogen. However, because clomiphene citrate is easy to administer, we typically give one course prior to initiating pulsatile gonadotropin-releasing hormone (GnRH) or gonadotropin therapy. For those who ovulate, clomiphene citrate can then be continued. (See  <a class="medical medical_review" href="/d/html/7407.html" rel="external">"Overview of ovulation induction", section on 'Patient-specific approach'</a>.)</p><p>In contrast, most ovulation induction strategies for women with primary ovarian insufficiency (premature ovarian failure) are unsuccessful, and we suggest against their use. These women should be offered the option of in vitro fertilization with donor oocytes. We do not suggest a trial of <a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">clomiphene</a> citrate in these women. (See  <a class="medical medical_review" href="/d/html/7426.html" rel="external">"Management of primary ovarian insufficiency (premature ovarian failure)", section on 'Fertility'</a>.)</p><p class="headingAnchor" id="H13"><span class="h1">HOW TO USE CLOMIPHENE CITRATE</span></p><p class="headingAnchor" id="H14"><span class="h2">Pretreatment evaluation</span><span class="headingEndMark"> — </span>Before initiating therapy, the presence of ovulatory dysfunction must be established. The menstrual history alone may be diagnostic (eg, one can be confident that ovulatory dysfunction is present in women with amenorrhea or irregular menses [&gt;45 day intermenstrual interval]). It is possible that women with cycles in the 35- to 45-day range have intermittent ovulations. We suggest that these women try to conceive on their own without therapy for several months. If they are unsuccessful, they should be referred for ovulation induction. If the diagnosis of ovulatory dysfunction is uncertain, additional testing should be performed. This can include simple, noninvasive tests such as basal body temperature and/or urinary luteinizing hormone (LH) monitoring, although a luteal phase serum <a class="drug drug_general" data-topicid="9817" href="/d/drug information/9817.html" rel="external">progesterone</a> level is more definitive  (<a class="graphic graphic_table graphicRef62767" href="/d/graphic/62767.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/d/html/7437.html" rel="external">"Evaluation of the menstrual cycle and timing of ovulation"</a>.)</p><p>Disorders of pituitary, adrenal, and thyroid origin that can cause anovulation should be excluded prior to the initiation of therapy as targeted treatment of these endocrinopathies can result in normal ovulation. (See  <a class="medical medical_review" href="/d/html/7396.html" rel="external">"Overview of infertility"</a>.)</p><p>The pretreatment evaluation should include [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>A complete history and physical examination.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Laboratory testing – Human chorionic gonadotropin (hCG), thyroid-stimulating hormone (TSH), and prolactin (PRL) to exclude pregnancy, thyroid disease, and hyperprolactinemia as causes of the ovulatory dysfunction, respectively, because these require different treatments. Serum follicle-stimulating hormone (FSH) should also be measured [<a href="#rid1">1</a>] as women diagnosed with primary ovarian insufficiency are unlikely to respond to <a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">clomiphene</a>. (See  <a class="medical medical_review" href="/d/html/7402.html" rel="external">"Evaluation and management of secondary amenorrhea"</a> and  <a class="medical medical_review" href="/d/html/7443.html" rel="external">"Clinical manifestations and diagnosis of primary ovarian insufficiency (premature ovarian failure)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Women with polycystic ovary syndrome (PCOS) and hirsutism should have a 17-hydroxyprogesterone measured; if nonclassic 21-hydroxylase deficiency is diagnosed, glucocorticoid therapy is a potential alternative for ovulation induction. (See  <a class="medical medical_review" href="/d/html/147.html" rel="external">"Diagnosis and treatment of nonclassic (late-onset) congenital adrenal hyperplasia due to 21-hydroxylase deficiency", section on '17-hydroxyprogesterone'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Women with PCOS and obesity should be screened for diabetes and encouraged to lose weight before considering ovulation induction.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Semen analysis of the partner to identify seminal abnormalities that might contribute to the infertility. (See  <a class="medical medical_review" href="/d/html/5445.html" rel="external">"Female infertility: Evaluation", section on 'Semen analysis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hysterosalpingogram if the clinical history suggests uterine or tubal pathology may also be present and in women over 35 years of age to avoid ineffective treatment when fertility is in decline. In women with no risk factors for tubal disease, the hysterosalpingogram can be postponed but should be performed if women have not conceived after three ovulatory cycles. (See  <a class="medical medical_review" href="/d/html/5445.html" rel="external">"Female infertility: Evaluation", section on 'Hysterosalpingogram'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An endometrial biopsy may be indicated to assess hyperplastic changes in women with chronic anovulation. This is not routine, however. Indications are described separately. (See  <a class="medical medical_review" href="/d/html/5476.html" rel="external">"Abnormal uterine bleeding in nonpregnant reproductive-age patients: Management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A pelvic examination or a pelvic ultrasound to rule out ovarian cysts, especially in patients with known tendency to form functional cysts.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Some experts suggest an assessment of ovarian follicle pool in women over age 37 years. A low serum anti-müllerian hormone (AMH) less than 1 ng/mL would identify a woman with a diminished pool of oocytes who would likely be triaged to assisted reproductive interventions (instead of <a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">clomiphene</a> citrate). (See  <a class="medical medical_review" href="/d/html/5445.html" rel="external">"Female infertility: Evaluation", section on 'Anti-müllerian hormone'</a>.)</p><p></p><p class="headingAnchor" id="H15"><span class="h2">Starting a cycle</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">Clomiphene</a> citrate therapy for ovulation induction is typically started on the fifth day of a cycle, following either spontaneous or induced bleeding. However, the results of therapy (in terms of ovulatory rates, pregnancy, or spontaneous miscarriage) are comparable when clomiphene is started on cycle day 2, 3, 4, or 5 [<a href="#rid18">18,19</a>].</p><p>There are no laboratory or clinical parameters that predict the dose necessary to achieve ovulation. The initial dose, empirically, is 50 mg daily for five days; starting with a higher dose does not result in higher pregnancy rates. If ovulation does not occur in the first cycle of treatment, the dose is increased to 100 mg. Thereafter, the dose is increased by increments of 50 mg to a maximum daily dose of 150 mg (100 mg is the maximum dose approved by the US Food and Drug Administration [FDA], and the American Society for Reproductive Medicine [ASRM] suggests that doses &gt;100 mg add little to clinical pregnancy rates) [<a href="#rid1">1</a>]. Once ovulation is achieved, the same dose should be continued for four to six cycles.</p><p>The LH surge occurs from 5 to 12 days after the last day of <a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">clomiphene</a> administration. The day of ovulation is generally consistent in each cycle once ovulation has been established. The couple is advised to have intercourse every other day for one week beginning <strong>five days</strong> after the last day of medication.</p><p>Because of the observations that pregnancy rates are low after six cycles of treatment and that 12 or more cycles may increase the risk of ovarian neoplasms [<a href="#rid20">20</a>], the American College of Obstetricians and Gynecologists (ACOG) has suggested that <a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">clomiphene</a> treatment be limited to fewer than 12 cycles and that the number of gonadotropin cycles be minimized, as well [<a href="#rid21">21</a>]. We suggest further evaluation and/or a change in therapy for women who do not conceive after three to six ovulatory clomiphene citrate cycles.</p><p class="headingAnchor" id="H16"><span class="h2">Monitoring</span><span class="headingEndMark"> — </span>The response to treatment should be monitored. Determination of the ovulatory LH surge by urinary LH kits is what most clinicians recommend in practice. Urinary LH monitoring also provides information on appropriate timing of intercourse during a given cycle [<a href="#rid22">22</a>]. The LH surge typically occurs 5 to 12 days after <a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">clomiphene</a> administration is completed. Ovulation generally occurs 14 to 26 hours after the detection of the urinary LH surge and almost always within 48 hours [<a href="#rid23">23</a>]. Therefore, the interval of highest fertility is the day of the LH surge and the following two days.</p><p>A basal body temperature chart can also be used and does not increase the cost of treatment. Conversion of a uniphasic to a biphasic basal temperature curve suggests retrospectively that ovulation has occurred. However, basal body temperature charting can be tedious for some patients and is not useful for timing of intercourse, as the temperature rise occurs one to five days after the midcycle LH surge and up to four days after ovulation.</p><p>A mid-luteal (one week after ovulation or one week before the expected menses) serum <a class="drug drug_general" data-topicid="9817" href="/d/drug information/9817.html" rel="external">progesterone</a> concentration greater than 3 ng/mL (ideally greater than 10 ng/mL) provides reliable evidence that ovulation has occurred. An endometrial biopsy to confirm the adequacy of the luteal phase is not recommended.</p><p>Some expert groups, such as the Royal College of Obstetricians and Gynecologists (RCOG) and the National Institute for Health and Clinical Excellence (NICE), suggest serial transvaginal ultrasound to monitor the number and size of developing follicles and to time hCG administration if necessary. Serial transvaginal ultrasound may also provide evidence of ovulation (follicle enlargement followed by collapse suggests ovulation). Some advocate ultrasound monitoring of just the first <a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">clomiphene</a> cycle in order to exclude hyper-response [<a href="#rid24">24,25</a>]. However, adding ultrasonographic monitoring is costly and does not appear to improve pregnancy rates significantly [<a href="#rid26">26</a>]. (See  <a class="medical medical_review" href="/d/html/7437.html" rel="external">"Evaluation of the menstrual cycle and timing of ovulation"</a>.)</p><p>Routine physical and ultrasound examinations to detect ovarian enlargement are not always necessary before every new treatment cycle but should be considered in symptomatic patients. The management of ovarian enlargement/theca lutein cysts from ovarian stimulation is controversial. We recommend withholding <a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">clomiphene</a> in these cases until the cyst(s) disappear either spontaneously or after suppression with oral contraceptive pills or gonadotropin-releasing hormone (GnRH) agonists.</p><p class="headingAnchor" id="H18"><span class="h1">OUTCOMES</span></p><p class="headingAnchor" id="H248089909"><span class="h2">Letrozole versus clomiphene</span><span class="headingEndMark"> — </span>Most, but not all, women with polycystic ovary syndrome (PCOS) ovulate in response to <a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">clomiphene</a> citrate. However, higher live birth rates have been observed with the aromatase inhibitor <a class="drug drug_general" data-topicid="10064" href="/d/drug information/10064.html" rel="external">letrozole</a>, particularly in patients with PCOS and obesity (see  <a class="medical medical_review" href="/d/html/7425.html" rel="external">"Ovulation induction with letrozole", section on 'Comparison with clomiphene'</a>). Many experts now suggest letrozole rather than clomiphene citrate for all women with PCOS. Ovulation induction is an off-label use of letrozole. Efficacy and safety are reviewed in detail separately. (See  <a class="medical medical_review" href="/d/html/7425.html" rel="external">"Ovulation induction with letrozole"</a>.)</p><p class="headingAnchor" id="H1946813591"><span class="h2">Clomiphene citrate</span></p><p class="headingAnchor" id="H783710815"><span class="h3">Ovulatory and pregnancy rates</span><span class="headingEndMark"> — </span>In women with PCOS, an ovulatory rate of 80 percent and a cumulative pregnancy rate of 30 to 40 percent can be expected [<a href="#rid3">3,27,28</a>]. The incidence of miscarriage and congenital anomalies appears to be similar to that in spontaneous pregnancies, and the rate of ectopic pregnancy is probably not increased [<a href="#rid29">29</a>]. The risk of ovarian hyperstimulation syndrome is less than 1 percent. The risk of multiple gestations is increased (7 percent in the trial noted above) [<a href="#rid17">17</a>]. (See <a class="local">'Multiple gestation'</a> below and <a class="local">'Perinatal outcome'</a> below and  <a class="medical medical_review" href="/d/html/7407.html" rel="external">"Overview of ovulation induction", section on 'Ovarian hyperstimulation syndrome'</a>.)</p><p>Of those who ovulate, approximately 50 percent do so at a dose of 50 mg [<a href="#rid24">24,30</a>], another 20 to 25 percent at 100 mg, and 10 percent at 150 mg [<a href="#rid27">27,28,31</a>]. There is no benefit to increasing the <a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">clomiphene</a> dose in subsequent cycles once ovulation occurs. A literature review including data from over 5000 patients with a variety of indications for clomiphene therapy reported an ovulation rate of 73 percent and a pregnancy rate of 36 percent [<a href="#rid32">32</a>]. Of patients who became pregnant, the miscarriage rate was approximately 20 percent and the multiple pregnancy rate was 8 to 13 percent. Almost all of the pregnancies that did not miscarry resulted in a live birth. A theoretical projection of the results of clomiphene induction of ovulation in 100 women concluded that 25 of the 100 would succeed in delivering a singleton healthy baby.</p><p>The ovulatory rate is lower with increasing age, body mass index (BMI), insulin resistance, and free androgen index  (<a class="graphic graphic_figure graphicRef81180" href="/d/graphic/81180.html" rel="external">figure 1</a>) [<a href="#rid1">1,33</a>]. (See  <a class="medical medical_review" href="/d/html/7407.html" rel="external">"Overview of ovulation induction", section on 'Clomiphene citrate'</a>.)</p><p>After six months of treatment, the pregnancy rate per cycle falls substantially despite regular ovulation [<a href="#rid34">34</a>]. In addition, pregnancy rates are lower among women who ovulate only after receiving higher doses of <a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">clomiphene</a>. Failure to conceive despite ovulatory cycles, particularly at higher doses, may be due to clomiphene's antiestrogenic effects on the quantity and quality of cervical mucus [<a href="#rid4">4</a>] and on the endometrium, impairing implantation [<a href="#rid12">12</a>]. (See <a class="local">'Endometrial effects'</a> below.)</p><p>As noted above, a hysterosalpingogram should be performed, if not already done, in any woman who fails to conceive within three to six treatment cycles (see <a class="local">'Pretreatment evaluation'</a> above). Failure to conceive after a maximum of six ovulatory treatment cycles indicates a need to further evaluate for factors potentially causing infertility or to change to another treatment strategy.</p><p class="headingAnchor" id="H783711825"><span class="h3">Multiple gestation</span><span class="headingEndMark"> — </span>Induction of ovulation by <a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">clomiphene</a> increases the probability of multifetal pregnancy: twins have been reported in 6.9 to 9 percent of pregnancies, triplets in 0.3 to 0.5 percent, quadruplets in 0.3 percent, and quintuplets in 0.13 percent [<a href="#rid3">3,35</a>]. The risk may be reduced by ultrasound monitoring and withholding human chorionic gonadotropin (hCG), intrauterine insemination (IUI), or intercourse if more than two follicles &gt;15 mm diameter are seen. Additional information on outcomes of multiple gestations is discussed elsewhere [<a href="#rid36">36</a>]. (See  <a class="medical medical_review" href="/d/html/4998.html" rel="external">"Neonatal complications of multiple births"</a>.)</p><p class="headingAnchor" id="H20"><span class="h3">Perinatal outcome</span><span class="headingEndMark"> — </span>Most [<a href="#rid28">28,37-40</a>], but not all [<a href="#rid41">41</a>], studies suggest that the frequencies of congenital malformations and spontaneous abortion are <strong>not</strong> increased in pregnancies after <a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">clomiphene</a> therapy. Similar findings have been reported for <a class="drug drug_general" data-topicid="10064" href="/d/drug information/10064.html" rel="external">letrozole</a>. (See  <a class="medical medical_review" href="/d/html/7425.html" rel="external">"Ovulation induction with letrozole", section on 'Fetal safety'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>In one report of 1034 pregnancies and 935 newborns after clomiphene-induced ovulation [<a href="#rid37">37</a>], spontaneous abortion and visible congenital malformations occurred in 14.2 and 2.3 percent, respectively; rates were comparable with those in mothers who spontaneously ovulated.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In contrast, a newer report by the National Birth Defects Prevention Study of the Centers for Disease Control and Prevention (CDC) examined 30 different congenital anomalies in a multicenter, case-control study of deliveries between 1997 and 2005 [<a href="#rid41">41</a>]. The exposure of interest was <a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">clomiphene</a> citrate use for two months before conception through the first month of pregnancy. Several significant associations between clomiphene use and congenital anomalies were observed, but because of the small number of cases in several categories and the inability to assess the effects of clomiphene separately from subfertility, these results should be interpreted with caution.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There is no evidence of developmental delays or learning disabilities in children whose mothers took <a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">clomiphene</a> [<a href="#rid42">42</a>]. Several studies have found a mildly increased risk of preterm birth in pregnancies (singleton and multiple) after assisted reproduction compared with natural pregnancies [<a href="#rid43">43-46</a>]. This effect has not been shown to be specific to clomiphene and is likely to be due, at least in part, to comorbidities in subfertile women [<a href="#rid47">47</a>] rather than the ovulation stimulation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There does not appear to be an increase in cancer risk in children conceived using ovulation induction drugs.</p><p></p><p class="headingAnchor" id="H1108466799"><span class="h3">Role of modified regimens</span></p><p class="headingAnchor" id="H1362636892"><span class="h4">Higher doses</span><span class="headingEndMark"> — </span>High-dose <a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">clomiphene</a> citrate (200 to 250 mg daily) may be given for 8 to 10 days in women who are refractory to standard doses. This extended regimen of clomiphene is sometimes used for women who cannot receive exogenous gonadotropins, but the overall experience is limited and the dose exceeds current US Food and Drug Administration (FDA) recommendations. We suggest against the use of these high doses. (See  <a class="medical medical_review" href="/d/html/7407.html" rel="external">"Overview of ovulation induction", section on 'Gonadotropin therapy'</a>.)</p><p class="headingAnchor" id="H2307191368"><span class="h4">Addition of ovulatory dose hCG</span><span class="headingEndMark"> — </span>An absent or inadequate midcycle luteinizing hormone (LH) surge may result in a failure to ovulate or a short luteal phase, despite clomiphene-induced follicular development. In this situation, exogenous hCG (single-dose 10,000 international units intramuscular [IM]) may be added to the regimen. It is given when transvaginal ultrasonography shows that the leading follicle has reached 18 to 20 mm in diameter [<a href="#rid48">48</a>]. It should be noted that premature administration of hCG acts like a premature LH surge and may result in follicular atresia.</p><p>In many institutions, hCG is routinely used to induce ovulation and to time IUI. However, we do not suggest routine administration of exogenous hCG for women in whom an endogenous LH surge can be detected, as it does not enhance the efficacy of clomiphene-IUI treatment in these women [<a href="#rid49">49-52</a>].</p><p>A progressive rise in the serum estradiol concentration is also evidence for advancing follicular development and maturation, but serial transvaginal ultrasound to monitor follicle size is superior and should be used to time hCG administration. Ovulation occurs approximately 36 to 44 hours after the injection.</p><p class="headingAnchor" id="H1228728856"><span class="h4">Other</span></p><p class="bulletIndent1"><span class="glyph">●</span>A progestin is often administered to "shed" the endometrium before starting <a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">clomiphene</a> in women with PCOS. However, available data suggest that conception and live birth rates may be lower in women after a spontaneous period or progestin-induced withdrawal bleed compared with anovulatory cycles without progestin withdrawal [<a href="#rid53">53</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9817" href="/d/drug information/9817.html" rel="external">Progesterone</a> supplementation may also be used for luteal phase support in women treated with <a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">clomiphene</a> citrate, although a benefit has not been demonstrated [<a href="#rid54">54</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Addition of IUI does not appear to improve pregnancy rates [<a href="#rid55">55</a>]. Therefore, we suggest against routinely adding IUI in women (without male factor infertility) undergoing ovulation induction with <a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">clomiphene</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>As noted above, <a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">clomiphene</a>, like <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a> and <a class="drug drug_general" data-topicid="9593" href="/d/drug information/9593.html" rel="external">raloxifene</a>, is a selective estrogen receptor modulator (SERM). Tamoxifen has been used as an ovulation induction agent, but clomiphene therapy resulted in a higher ovulation rate in one randomized trial (64 versus 52 percent for clomiphene and tamoxifen, respectively) [<a href="#rid56">56</a>]. In a second trial, clomiphene and raloxifene were similarly effective in inducing ovulation [<a href="#rid57">57</a>].</p><p></p><p class="headingAnchor" id="H21"><span class="h3">Adverse effects</span></p><p class="headingAnchor" id="H783710475"><span class="h4">Common side effects</span><span class="headingEndMark"> — </span>Hot flashes are common, occurring in 10 to 20 percent of women [<a href="#rid21">21,58</a>]. They may result from hypoestrogenism at the hypothalamic level due to <a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">clomiphene</a> blockade of estrogen receptors. Additional problems related to the hyperestrogenic environment induced by clomiphene citrate include abdominal distention and pain (5.5 percent), nausea and vomiting (2.2 percent), and breast discomfort (2 percent). These symptoms abate soon after cessation of therapy.</p><p>Mood swings, depression, and headaches can also occur but are rarely serious enough to consider terminating treatment.</p><p>Side effects of <a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">clomiphene</a> are not dose related, as they can occur at the 50 mg dose. Uncomplicated ovarian enlargement develops in approximately 14 percent of women, but true ovarian hyperstimulation syndrome is rare. (See  <a class="medical medical_review" href="/d/html/7407.html" rel="external">"Overview of ovulation induction", section on 'Multiple gestation'</a>.)</p><p>We withhold <a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">clomiphene</a> in women with ovarian enlargement and/or cyst(s) until the ovaries return to pretreatment size. Ovarian enlargement can be assessed by symptoms and pelvic examination; routine ultrasound monitoring is unnecessary.</p><p class="headingAnchor" id="H783710461"><span class="h4">Visual disturbances</span><span class="headingEndMark"> — </span>Visual symptoms, such as blurring, double vision, and/or scotomata, develop in 1 to 2 percent of women and are usually reversible. However, because they may persist, their onset warrants discontinuation of therapy [<a href="#rid59">59</a>]. They have been thought to represent retinal toxicity, but in one study of eight women with clomiphene-associated visual blurring or persistent afterimages, rechallenge appeared to affect the visual cortex rather than the retina [<a href="#rid60">60</a>].</p><p class="headingAnchor" id="H783710468"><span class="h4">Endometrial effects</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">Clomiphene</a> citrate, while used to improve luteal function, may also cause an iatrogenic luteal phase defect when used to induce ovulation in anovulatory women [<a href="#rid61">61</a>]. The mechanism may be related to antiestrogenic effects of clomiphene citrate on the endometrium or inhibition of steroidogenesis in granulosa and lutein cells. Increasing the dose of clomiphene does not correct the luteal phase defect. However, preovulatory hCG and/or supplemental <a class="drug drug_general" data-topicid="9817" href="/d/drug information/9817.html" rel="external">progesterone</a> may prevent the problem.</p><p class="headingAnchor" id="H783710671"><span class="h5">Strategies to prevent thin endometrium</span><span class="headingEndMark"> — </span>Strategies such as giving half-dose <a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">clomiphene</a> (25 mg/day), early administration (starting day 1), or adding exogenous estrogen have been tried to minimize the antiestrogenic effect of clomiphene on the endometrium, with limited success.</p><p class="headingAnchor" id="H783713907"><span class="h4">Cancer risks</span><span class="headingEndMark"> — </span>The use of <a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">clomiphene</a> citrate for ovulation induction does not appear to be associated with an excess risk of ovarian or breast cancer. This topic is reviewed in detail separately. (See  <a class="medical medical_review" href="/d/html/7407.html" rel="external">"Overview of ovulation induction", section on 'Cancer risks'</a>.)</p><p>One retrospective cohort study reported an excess risk of endometrial cancer with <a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">clomiphene</a>, but this has not been confirmed [<a href="#rid62">62</a>]. The relatively small number of uterine cancers and incomplete ascertainment of cases preclude a definite conclusion regarding uterine cancer risk. This study does not provide sufficient evidence to change current recommendations for clomiphene use. (See  <a class="medical medical_review" href="/d/html/3249.html" rel="external">"Endometrial carcinoma: Epidemiology, risk factors, and prevention"</a>.)</p><p class="headingAnchor" id="H2353903780"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/110097.html" rel="external">"Society guideline links: Polycystic ovary syndrome"</a> and  <a class="medical medical_society_guidelines" href="/d/html/114191.html" rel="external">"Society guideline links: Female infertility"</a>.)</p><p class="headingAnchor" id="H38"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>The best candidates for <a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">clomiphene</a> citrate are women with polycystic ovary syndrome (PCOS). While clomiphene has been the most widely used ovulation induction agent for these women for many years, <a class="drug drug_general" data-topicid="10064" href="/d/drug information/10064.html" rel="external">letrozole</a> appears to result in higher live birth rates. For this reason, it is becoming the drug of choice  (<a class="graphic graphic_table graphicRef56718" href="/d/graphic/56718.html" rel="external">table 1</a>). (See <a class="local">'Polycystic ovary syndrome'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For oligoovulatory women with PCOS undergoing ovulation induction, we now suggest <a class="drug drug_general" data-topicid="10064" href="/d/drug information/10064.html" rel="external">letrozole</a> as first-line therapy over <a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">clomiphene</a> citrate, (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). Before starting letrozole, the clinician <strong>must</strong> discuss that this use of the drug is not US Food and Drug Administration (FDA) approved and that clomiphene is an alternative. (See  <a class="medical medical_review" href="/d/html/7425.html" rel="external">"Ovulation induction with letrozole", section on 'Suggested approach'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For women with PCOS and a body mass index (BMI) &gt;30 kg/m<sup>2</sup>, we also suggest diet and exercise to promote weight loss. (See  <a class="medical medical_review" href="/d/html/7421.html" rel="external">"Treatment of polycystic ovary syndrome in adults", section on 'Women pursuing pregnancy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Women with hypogonadotropic hypogonadism (hypothalamic amenorrhea) are hypoestrogenemic and are therefore unlikely to respond to <a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">clomiphene</a> citrate, an antiestrogen. However, because clomiphene citrate is easy to administer, we suggest giving one course of clomiphene citrate prior to initiating pulsatile gonadotropin-releasing hormone (GnRH) or gonadotropin therapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). For those who ovulate, clomiphene citrate can then be continued. (See <a class="local">'Other ovulatory disorders'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Most ovulation induction strategies for women with primary ovarian insufficiency (premature ovarian failure) are unsuccessful, and we suggest against their use. These women should be offered the option of in vitro fertilization with donor oocytes. We do not suggest a trial of <a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">clomiphene</a> citrate in these women. (See <a class="local">'Other ovulatory disorders'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">Clomiphene</a> is initially begun on cycle day 3, 4, or 5 at a dose of 50 mg daily for five days. If ovulation does not occur in the first cycle of treatment, the dose is increased to 100 mg. Thereafter, the dose is increased by increments of 50 mg to a maximum daily dose of 150 mg until ovulation is achieved. The couple is advised to have intercourse every other day for one week beginning five days after the last day of medication. (See <a class="local">'How to use clomiphene citrate'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Most clinicians have their patients use home urinary luteinizing hormone (LH) kits for monitoring their cycles. A mid-luteal serum <a class="drug drug_general" data-topicid="9817" href="/d/drug information/9817.html" rel="external">progesterone</a> level may be obtained once to document that <a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">clomiphene</a> citrate caused ovulation. Serial transvaginal ultrasound may also be used, although it increases the cost without having a significant effect on pregnancy rates. (See <a class="local">'Monitoring'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Further evaluation or change in therapy is indicated for women who do not conceive after having six ovulatory cycles. (See <a class="local">'Starting a cycle'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Risks and complications should be discussed. The most common of these are hot flashes (10 to 20 percent), uncomplicated ovarian enlargement (14 percent), and multiple gestation (primarily twins, &lt;10 percent). True ovarian hyperstimulation is rare. Less frequent side effects include abdominal distention and pain, nausea/vomiting, breast discomfort, visual symptoms, mood swings, and headaches. Visual symptoms warrant discontinuation of therapy. (See <a class="local">'Adverse effects'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">Clomiphene</a> citrate does not appear to be associated with adverse perinatal outcomes or an increased risk of congenital malformations. (See <a class="local">'Perinatal outcome'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For women who are being monitored with ultrasound, exogenous human chorionic gonadotropin (hCG; single-dose 10,000 international units intramuscular [IM]) is indicated in women who have an absent or inadequate midcycle LH surge. (See <a class="local">'Addition of ovulatory dose hCG'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Practice Committee of the American Society for Reproductive Medicine. Use of clomiphene citrate in infertile women: a committee opinion. Fertil Steril 2013; 100:341.</a></li><li><a class="nounderline abstract_t">Glasier AF, Irvine DS, Wickings EJ, et al. A comparison of the effects on follicular development between clomiphene citrate, its two separate isomers and spontaneous cycles. Hum Reprod 1989; 4:252.</a></li><li><a class="nounderline abstract_t">Dickey RP, Holtkamp DE. Development, pharmacology and clinical experience with clomiphene citrate. Hum Reprod Update 1996; 2:483.</a></li><li><a class="nounderline abstract_t">Kettel LM, Roseff SJ, Berga SL, et al. Hypothalamic-pituitary-ovarian response to clomiphene citrate in women with polycystic ovary syndrome. Fertil Steril 1993; 59:532.</a></li><li><a class="nounderline abstract_t">Jorgensen SE, Starup J, Roos J, Micic S. Studies on the mode of action of clomiphene citrate. Acta Obstet Gynecol Scand 1976; 55:337.</a></li><li><a class="nounderline abstract_t">Kerin JF, Liu JH, Phillipou G, Yen SS. Evidence for a hypothalamic site of action of clomiphene citrate in women. J Clin Endocrinol Metab 1985; 61:265.</a></li><li><a class="nounderline abstract_t">Hsueh AJ, Erickson GF, Yen SS. Sensitisation of pituitary cells to luteinising hormone releasing hormone by clomiphene citrate in vitro. Nature 1978; 273:57.</a></li><li><a class="nounderline abstract_t">Kessel B, Hsueh AJ. Clomiphene citrate augments follicle-stimulating hormone-induced luteinizing hormone receptor content in cultured rat granulosa cells. Fertil Steril 1987; 47:334.</a></li><li><a class="nounderline abstract_t">Eden JA, Place J, Carter GD, et al. The effect of clomiphene citrate on follicular phase increase in endometrial thickness and uterine volume. Obstet Gynecol 1989; 73:187.</a></li><li><a class="nounderline abstract_t">Dehbashi S, Parsanezhad ME, Alborzi S, Zarei A. Effect of clomiphene citrate on endometrium thickness and echogenic patterns. Int J Gynaecol Obstet 2003; 80:49.</a></li><li><a class="nounderline abstract_t">Bonhoff AJ, Naether OG, Johannisson E. Effects of clomiphene citrate stimulation on endometrial structure in infertile women. Hum Reprod 1996; 11:844.</a></li><li><a class="nounderline abstract_t">Sereepapong W, Suwajanakorn S, Triratanachat S, et al. Effects of clomiphene citrate on the endometrium of regularly cycling women. Fertil Steril 2000; 73:287.</a></li><li><a class="nounderline abstract_t">Li TC, Warren MA, Murphy C, et al. A prospective, randomised, cross-over study comparing the effects of clomiphene citrate and cyclofenil on endometrial morphology in the luteal phase of normal, fertile women. Br J Obstet Gynaecol 1992; 99:1008.</a></li><li><a class="nounderline abstract_t">Thompson LA, Barratt CL, Thornton SJ, et al. The effects of clomiphene citrate and cyclofenil on cervical mucus volume and receptivity over the periovulatory period. Fertil Steril 1993; 59:125.</a></li><li><a class="nounderline abstract_t">Gelety TJ, Buyalos RP. The effect of clomiphene citrate and menopausal gonadotropins on cervical mucus in ovulatory cycles. Fertil Steril 1993; 60:471.</a></li><li><a class="nounderline abstract_t">Roumen FJ. [Decreased quality of cervix mucus under the influence of clomiphene: a meta-analysis]. Ned Tijdschr Geneeskd 1997; 141:2401.</a></li><li><a class="nounderline abstract_t">Legro RS, Brzyski RG, Diamond MP, et al. Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. N Engl J Med 2014; 371:119.</a></li><li><a class="nounderline abstract_t">Wu CH, Winkel CA. The effect of therapy initiation day on clomiphene citrate therapy. Fertil Steril 1989; 52:564.</a></li><li><a class="nounderline abstract_t">Dehbashi S, Vafaei H, Parsanezhad MD, Alborzi S. Time of initiation of clomiphene citrate and pregnancy rate in polycystic ovarian syndrome. Int J Gynaecol Obstet 2006; 93:44.</a></li><li><a class="nounderline abstract_t">Rossing MA, Daling JR, Weiss NS, et al. Ovarian tumors in a cohort of infertile women. N Engl J Med 1994; 331:771.</a></li><li><a class="nounderline abstract_t">ACOG Committee on Practice Bulletins-Gynecology. ACOG Practice Bulletin. Clinical management guidelines for obstetrician-gynecologists number 34, February 2002. Management of infertility caused by ovulatory dysfunction. American College of Obstetricians and Gynecologists. Obstet Gynecol 2002; 99:347.</a></li><li><a class="nounderline abstract_t">O'Herlihy C, De Crespigny LJ, Robinson HP. Monitoring ovarian follicular development with real-time ultrasound. Br J Obstet Gynaecol 1980; 87:613.</a></li><li><a class="nounderline abstract_t">Miller PB, Soules MR. The usefulness of a urinary LH kit for ovulation prediction during menstrual cycles of normal women. Obstet Gynecol 1996; 87:13.</a></li><li><a class="nounderline abstract_t">Kousta E, White DM, Franks S. Modern use of clomiphene citrate in induction of ovulation. Hum Reprod Update 1997; 3:359.</a></li><li><a class="nounderline abstract_t">Vause TD, Cheung AP, Sierra S, et al. Ovulation induction in polycystic ovary syndrome: No. 242, May 2010. Int J Gynaecol Obstet 2010; 111:95.</a></li><li><a class="nounderline abstract_t">Smith YR, Randolph JF Jr, Christman GM, et al. Comparison of low-technology and high-technology monitoring of clomiphene citrate ovulation induction. Fertil Steril 1998; 70:165.</a></li><li><a class="nounderline abstract_t">Gorlitsky GA, Kase NG, Speroff L. Ovulation and pregnancy rates with clomiphene citrate. Obstet Gynecol 1978; 51:265.</a></li><li><a class="nounderline abstract_t">Gysler M, March CM, Mishell DR Jr, Bailey EJ. A decade's experience with an individualized clomiphene treatment regimen including its effect on the postcoital test. Fertil Steril 1982; 37:161.</a></li><li><a class="nounderline abstract_t">Dickey RP, Matis R, Olar TT, et al. The occurrence of ectopic pregnancy with and without clomiphene citrate use in assisted and nonassisted reproductive technology. J In Vitro Fert Embryo Transf 1989; 6:294.</a></li><li><a class="nounderline abstract_t">Glasier AF. Clomiphene citrate. Baillieres Clin Obstet Gynaecol 1990; 4:491.</a></li><li><a class="nounderline abstract_t">Rostami-Hodjegan A, Lennard MS, Tucker GT, Ledger WL. Monitoring plasma concentrations to individualize treatment with clomiphene citrate. Fertil Steril 2004; 81:1187.</a></li><li><a class="nounderline abstract_t">Homburg R. Clomiphene citrate--end of an era? A mini-review. Hum Reprod 2005; 20:2043.</a></li><li><a class="nounderline abstract_t">Imani B, Eijkemans MJ, te Velde ER, et al. Predictors of chances to conceive in ovulatory patients during clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility. J Clin Endocrinol Metab 1999; 84:1617.</a></li><li><a class="nounderline abstract_t">Macgregor AH, Johnson JE, Bunde CA. Further clinical experience with clomiphene citrate. Fertil Steril 1968; 19:616.</a></li><li><a class="nounderline abstract_t">Scialli AR. The reproductive toxicity of ovulation induction. Fertil Steril 1986; 45:315.</a></li><li><a class="nounderline abstract_t">McDowell S, Kroon B, Yazdani A. Clomiphene ovulation induction and higher-order multiple pregnancy. Aust N Z J Obstet Gynaecol 2013; 53:395.</a></li><li><a class="nounderline abstract_t">Kurachi K, Aono T, Minagawa J, Miyake A. Congenital malformations of newborn infants after clomiphene-induced ovulation. Fertil Steril 1983; 40:187.</a></li><li><a class="nounderline abstract_t">Dickey RP, Taylor SN, Curole DN, et al. Incidence of spontaneous abortion in clomiphene pregnancies. Hum Reprod 1996; 11:2623.</a></li><li><a class="nounderline abstract_t">Sørensen HT, Pedersen L, Skriver MV, et al. Use of clomifene during early pregnancy and risk of hypospadias: population based case-control study. BMJ 2005; 330:126.</a></li><li class="breakAll">REPROTOX: An information system on environmental hazards to human reproduction and development. Agent #1242 www.reprotox.org (Accessed on August 20, 2008).</li><li><a class="nounderline abstract_t">Reefhuis J, Honein MA, Schieve LA, et al. Use of clomiphene citrate and birth defects, National Birth Defects Prevention Study, 1997-2005. Hum Reprod 2011; 26:451.</a></li><li><a class="nounderline abstract_t">Hack M, Brish M, Serr DM, et al. Outcome of pregnancy after induced ovulation. Follow-up of pregnancies and children born after clomiphene therapy. JAMA 1972; 220:1329.</a></li><li><a class="nounderline abstract_t">Lambalk CB, van Hooff M. Natural versus induced twinning and pregnancy outcome: a Dutch nationwide survey of primiparous dizygotic twin deliveries. Fertil Steril 2001; 75:731.</a></li><li><a class="nounderline abstract_t">Olivennes F, Rufat P, André B, et al. The increased risk of complication observed in singleton pregnancies resulting from in-vitro fertilization (IVF) does not seem to be related to the IVF method itself. Hum Reprod 1993; 8:1297.</a></li><li><a class="nounderline abstract_t">Pregnancies and births resulting from in vitro fertilization: French national registry, analysis of data 1986 to 1990. FIVNAT (French In Vitro National). Fertil Steril 1995; 64:746.</a></li><li><a class="nounderline abstract_t">Källén B, Olausson PO, Nygren KG. Neonatal outcome in pregnancies from ovarian stimulation. Obstet Gynecol 2002; 100:414.</a></li><li><a class="nounderline abstract_t">Gaudoin M, Dobbie R, Finlayson A, et al. Ovulation induction/intrauterine insemination in infertile couples is associated with low-birth-weight infants. Am J Obstet Gynecol 2003; 188:611.</a></li><li><a class="nounderline abstract_t">O'Herlihy C, Pepperell RJ, Robinson HP. Ultrasound timing of human chorionic gonadotropin administration in clomiphene-stimulated cycle. Obstet Gynecol 1982; 59:40.</a></li><li><a class="nounderline abstract_t">Brown J, Farquhar C, Beck J, et al. Clomiphene and anti-oestrogens for ovulation induction in PCOS. Cochrane Database Syst Rev 2009; :CD002249.</a></li><li><a class="nounderline abstract_t">Deaton JL, Clark RR, Pittaway DE, et al. Clomiphene citrate ovulation induction in combination with a timed intrauterine insemination: the value of urinary luteinizing hormone versus human chorionic gonadotropin timing. Fertil Steril 1997; 68:43.</a></li><li><a class="nounderline abstract_t">Zreik TG, García-Velasco JA, Habboosh MS, et al. Prospective, randomized, crossover study to evaluate the benefit of human chorionic gonadotropin-timed versus urinary luteinizing hormone-timed intrauterine inseminations in clomiphene citrate-stimulated treatment cycles. Fertil Steril 1999; 71:1070.</a></li><li><a class="nounderline abstract_t">Kosmas IP, Tatsioni A, Fatemi HM, et al. Human chorionic gonadotropin administration vs. luteinizing monitoring for intrauterine insemination timing, after administration of clomiphene citrate: a meta-analysis. Fertil Steril 2007; 87:607.</a></li><li><a class="nounderline abstract_t">Diamond MP, Kruger M, Santoro N, et al. Endometrial shedding effect on conception and live birth in women with polycystic ovary syndrome. Obstet Gynecol 2012; 119:902.</a></li><li><a class="nounderline abstract_t">Miralpeix E, González-Comadran M, Solà I, et al. Efficacy of luteal phase support with vaginal progesterone in intrauterine insemination: a systematic review and meta-analysis. J Assist Reprod Genet 2014; 31:89.</a></li><li><a class="nounderline abstract_t">Abu Hashim H, Ombar O, Abd Elaal I. Intrauterine insemination versus timed intercourse with clomiphene citrate in polycystic ovary syndrome: a randomized controlled trial. Acta Obstet Gynecol Scand 2011; 90:344.</a></li><li><a class="nounderline abstract_t">Badawy A, Gibreal A. Clomiphene citrate versus tamoxifen for ovulation induction in women with PCOS: a prospective randomized trial. Eur J Obstet Gynecol Reprod Biol 2011; 159:151.</a></li><li><a class="nounderline abstract_t">de Paula Guedes Neto E, Savaris RF, von Eye Corleta H, et al. Prospective, randomized comparison between raloxifene and clomiphene citrate for ovulation induction in polycystic ovary syndrome. Fertil Steril 2011; 96:769.</a></li><li><a class="nounderline abstract_t">Jones GS, De Moraes-Ruehsen M. Induction of ovulation with human gonadotropins and with clomiphene. Fertil Steril 1965; 16:461.</a></li><li><a class="nounderline abstract_t">Purvin VA. Visual disturbance secondary to clomiphene citrate. Arch Ophthalmol 1995; 113:482.</a></li><li><a class="nounderline abstract_t">Racette L, Casson PR, Claman P, et al. An investigation of the visual disturbances experienced by patients on clomiphene citrate. Fertil Steril 2010; 93:1169.</a></li><li><a class="nounderline abstract_t">Keenan JA, Herbert CM, Bush JR, Wentz AC. Diagnosis and management of out-of-phase endometrial biopsies among patients receiving clomiphene citrate for ovulation induction. Fertil Steril 1989; 51:964.</a></li><li><a class="nounderline abstract_t">Althuis MD, Moghissi KS, Westhoff CL, et al. Uterine cancer after use of clomiphene citrate to induce ovulation. Am J Epidemiol 2005; 161:607.</a></li></ol></div><div id="topicVersionRevision">Topic 7400 Version 27.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23809505" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Use of clomiphene citrate in infertile women: a committee opinion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2497133" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : A comparison of the effects on follicular development between clomiphene citrate, its two separate isomers and spontaneous cycles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9111183" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Development, pharmacology and clinical experience with clomiphene citrate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8458453" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Hypothalamic-pituitary-ovarian response to clomiphene citrate in women with polycystic ovary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/973563" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Studies on the mode of action of clomiphene citrate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3924949" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Evidence for a hypothalamic site of action of clomiphene citrate in women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/357983" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Sensitisation of pituitary cells to luteinising hormone releasing hormone by clomiphene citrate in vitro.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3028869" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Clomiphene citrate augments follicle-stimulating hormone-induced luteinizing hormone receptor content in cultured rat granulosa cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2492092" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The effect of clomiphene citrate on follicular phase increase in endometrial thickness and uterine volume.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12527460" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Effect of clomiphene citrate on endometrium thickness and echogenic patterns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8671338" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Effects of clomiphene citrate stimulation on endometrial structure in infertile women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10685531" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Effects of clomiphene citrate on the endometrium of regularly cycling women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1477004" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : A prospective, randomised, cross-over study comparing the effects of clomiphene citrate and cyclofenil on endometrial morphology in the luteal phase of normal, fertile women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8419199" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The effects of clomiphene citrate and cyclofenil on cervical mucus volume and receptivity over the periovulatory period.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8375529" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The effect of clomiphene citrate and menopausal gonadotropins on cervical mucus in ovulatory cycles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9554161" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : [Decreased quality of cervix mucus under the influence of clomiphene: a meta-analysis].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25006718" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Letrozole versus clomiphene for infertility in the polycystic ovary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2806595" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The effect of therapy initiation day on clomiphene citrate therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16530767" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Time of initiation of clomiphene citrate and pregnancy rate in polycystic ovarian syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8065405" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Ovarian tumors in a cohort of infertile women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11814521" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : ACOG Practice Bulletin. Clinical management guidelines for obstetrician-gynecologists number 34, February 2002. Management of infertility caused by ovulatory dysfunction. American College of Obstetricians and Gynecologists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7426518" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Monitoring ovarian follicular development with real-time ultrasound.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8532248" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The usefulness of a urinary LH kit for ovulation prediction during menstrual cycles of normal women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9459281" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Modern use of clomiphene citrate in induction of ovulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20848729" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Ovulation induction in polycystic ovary syndrome: No. 242, May 2010.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9660442" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Comparison of low-technology and high-technology monitoring of clomiphene citrate ovulation induction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/628527" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Ovulation and pregnancy rates with clomiphene citrate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7060766" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : A decade's experience with an individualized clomiphene treatment regimen including its effect on the postcoital test.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2698906" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : The occurrence of ectopic pregnancy with and without clomiphene citrate use in assisted and nonassisted reproductive technology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2282740" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Clomiphene citrate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15136073" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Monitoring plasma concentrations to individualize treatment with clomiphene citrate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15878925" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Clomiphene citrate--end of an era? A mini-review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10323389" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Predictors of chances to conceive in ovulatory patients during clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5660246" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Further clinical experience with clomiphene citrate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3081379" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : The reproductive toxicity of ovulation induction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23829327" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Clomiphene ovulation induction and higher-order multiple pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6873315" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Congenital malformations of newborn infants after clomiphene-induced ovulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9021363" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Incidence of spontaneous abortion in clomiphene pregnancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15613365" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Use of clomifene during early pregnancy and risk of hypospadias: population based case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15613365" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Use of clomifene during early pregnancy and risk of hypospadias: population based case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21112952" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Use of clomiphene citrate and birth defects, National Birth Defects Prevention Study, 1997-2005.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5067323" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Outcome of pregnancy after induced ovulation. Follow-up of pregnancies and children born after clomiphene therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11287027" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Natural versus induced twinning and pregnancy outcome: a Dutch nationwide survey of primiparous dizygotic twin deliveries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8408531" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : The increased risk of complication observed in singleton pregnancies resulting from in-vitro fertilization (IVF) does not seem to be related to the IVF method itself.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7672146" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Pregnancies and births resulting from in vitro fertilization: French national registry, analysis of data 1986 to 1990. FIVNAT (French In Vitro National).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12220758" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Neonatal outcome in pregnancies from ovarian stimulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12634629" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Ovulation induction/intrauterine insemination in infertile couples is associated with low-birth-weight infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7078848" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Ultrasound timing of human chorionic gonadotropin administration in clomiphene-stimulated cycle.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19821295" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Clomiphene and anti-oestrogens for ovulation induction in PCOS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9207582" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Clomiphene citrate ovulation induction in combination with a timed intrauterine insemination: the value of urinary luteinizing hormone versus human chorionic gonadotropin timing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10360912" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Prospective, randomized, crossover study to evaluate the benefit of human chorionic gonadotropin-timed versus urinary luteinizing hormone-timed intrauterine inseminations in clomiphene citrate-stimulated treatment cycles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17173907" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Human chorionic gonadotropin administration vs. luteinizing monitoring for intrauterine insemination timing, after administration of clomiphene citrate: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22525900" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Endometrial shedding effect on conception and live birth in women with polycystic ovary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24189966" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Efficacy of luteal phase support with vaginal progesterone in intrauterine insemination: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21306326" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Intrauterine insemination versus timed intercourse with clomiphene citrate in polycystic ovary syndrome: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21831503" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Clomiphene citrate versus tamoxifen for ovulation induction in women with PCOS: a prospective randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21782166" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Prospective, randomized comparison between raloxifene and clomiphene citrate for ovulation induction in polycystic ovary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5874268" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Induction of ovulation with human gonadotropins and with clomiphene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7710399" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Visual disturbance secondary to clomiphene citrate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19135656" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : An investigation of the visual disturbances experienced by patients on clomiphene citrate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2721730" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Diagnosis and management of out-of-phase endometrial biopsies among patients receiving clomiphene citrate for ovulation induction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15781949" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Uterine cancer after use of clomiphene citrate to induce ovulation.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
